The ​Promise of Yeztugo and ⁤the Challenges of Access

A new HIV prevention medication, yeztugo, developed by Gilead ‌Sciences (GILD), offers a‍ potentially transformative approach to combating the ongoing ⁤HIV epidemic.⁢ Approved in June for individuals at high risk, clinical trials demonstrated nearly 100% ​effectiveness in preventing infection, sparking ⁣renewed optimism in‌ public health circles.‍ Though, access to this groundbreaking ‌treatment is ⁤already facing significant obstacles, ‌particularly concerning insurance coverage.

CVS Caremark’s Decision and‍ the Role of Pharmacy Benefit Managers

As the largest pharmacy manager⁢ in the United States,CVS Health (CVS)‘s coverage decisions carry considerable weight. ⁣ The company has initially decided not to include Yeztugo in its commercial plans, a move⁤ that drew​ immediate ⁤criticism ⁣from ​AIDS advocacy groups. CVS cited clinical, financial, ‍and regulatory factors as justification, stating its Affordable Care Act (ACA) prevention program adheres to recommendations from​ the U.S. Department of Health and Human Services (HHS). Currently, the HHS-supported U.S. Preventive Services Task Force (USPSTF) only recommends three older HIV prevention medications.

This situation‌ highlights ‌the significant ‍influence of Pharmacy Benefit Managers (PBMs)‌ like CVS Caremark,⁣ OptumRx (UNH), ⁤and Express Scripts (CI). These ⁢intermediaries negotiate discounts with pharmaceutical manufacturers on behalf of employers and health insurers, collectively managing approximately 70%​ of prescription drug benefits in the‍ U.S.

Negotiations and Broader⁤ Coverage Trends

Sources​ indicate that ⁢Gilead is actively negotiating with​ CVS regarding Yeztugo’s inclusion. ​While CVS has initially declined coverage, other entities are⁣ moving forward. State health programs, including the⁣ veteran’s Administration and Medicare, have already added Yeztugo to their formularies. Furthermore, gilead reports that several state Medicaid⁤ programs, including California and New York, now cover ‌the medication. The⁤ company projects 75% coverage by U.S. insurers by the end of the year, increasing to 90%⁢ by June 2026.

OptumRx ⁢has‍ announced it⁢ will review Yeztugo ‍for inclusion​ in⁣ its formulary in the coming ​weeks, while Express Scripts has not yet responded to requests for comment.

The Cost Factor and⁢ the Potential for Prevention

The high list price of Yeztugo – exceeding $28,000 annually for a twice-yearly injection – is ‍a central point of contention. Mitchell Warren, managing director of the non-profit AIDS association AVAC, described the decision‍ as a “missed possibility,” arguing that the ‌price structure is prohibitive.However, Gilead CEO Daniel O’Day emphasizes‍ the long-term cost-effectiveness of preventative treatment, noting that the lifetime cost ‌of treating an HIV patient can exceed ‍$1 million.

The ⁤potential impact of Yeztugo is substantial. HIV continues ⁢to infect 1.3 million people each year globally, and has claimed over 42 million lives according to estimates​ from the World Health Organization. A highly effective preventative measure ​like Yeztugo could be instrumental in ⁢ending the​ 44-year-old epidemic.

Political and regulatory Considerations

Recent developments in the legal landscape ⁢could also influence the future of preventative care coverage. A⁤ recent Supreme Court ruling affirming the broad powers of the HHS regarding the USPSTF recommendations has raised concerns among some analysts. Reports that‌ Robert F. Kennedy Jr. may seek to replace members of the task force have also prompted alarm within medical groups, potentially impacting future coverage decisions.